Zeria Pharmaceutical Co (TSE:4559) Cyclically Adjusted Revenue per Share: 円1,604.21 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4559 Zeria Pharmaceutical Co Ltd TSE:4559
85 GF Score
Price 円2,120.00
GF Value 円2,509.92
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Zeria Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Zeria Pharmaceutical Co TSE:4559 +0.76% 85 Cyclically Adjusted Revenue per Share is 円1,604.21 as of Mar. 2026. GuruFocus rates TSE:4559 with a GF Score™ of 85/100 and a GF Value™ of 円2,509.92 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zeria Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円569.025. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,604.21 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zeria Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zeria Pharmaceutical Co was 6.40% per year. The lowest was 0.90% per year. And the median was 3.05% per year.

As of today (2026-07-29), Zeria Pharmaceutical Co's current stock price is 円2120.00. Zeria Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円1,604.21. Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.32.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zeria Pharmaceutical Co was 2.08. The lowest was 1.23. And the median was 1.60.


Zeria Pharmaceutical Co  (TSE:4559) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2120.00/1604.21
=1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zeria Pharmaceutical Co was 2.08. The lowest was 1.23. And the median was 1.60.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zeria Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Zeria Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zeria Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zeria Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Zeria Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,264.77 1,332.57 1,393.56 1,514.56 1,604.21

Zeria Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,514.56 1,535.48 1,552.62 1,584.98 1,604.21

TSE:4559 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeria Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4559
85GF Score
Zeria Pharmaceutical Co Ltd TSE:4559
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zeria Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zeria Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=569.025/112.7000*112.7000
=569.025

Current CPI (Mar. 2026) = 112.7000.

Zeria Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 310.424 98.100 356.624
201609 297.867 98.000 342.547
201612 314.642 98.400 360.367
201703 298.195 98.100 342.575
201706 300.826 98.500 344.194
201709 319.164 98.800 364.067
201712 338.814 99.400 384.148
201803 295.362 99.200 335.557
201806 303.125 99.200 344.377
201809 303.577 99.900 342.474
201812 336.647 99.700 380.543
201903 301.659 99.700 340.993
201906 318.200 99.800 359.330
201909 326.578 100.100 367.686
201912 344.217 100.500 386.003
202003 304.821 100.300 342.506
202006 275.221 99.900 310.485
202009 277.121 99.900 312.628
202012 322.000 99.300 365.452
202103 270.687 99.900 305.370
202106 297.231 99.500 336.663
202109 333.589 100.100 375.579
202112 365.993 100.100 412.062
202203 322.371 101.100 359.359
202206 367.971 101.800 407.371
202209 394.294 103.100 431.008
202212 408.147 104.100 441.865
202303 377.707 104.400 407.735
202306 415.257 105.200 444.862
202309 416.830 106.200 442.342
202312 481.869 106.800 508.489
202403 403.945 107.200 424.670
202406 486.748 108.200 506.992
202409 475.652 108.900 492.250
202412 507.050 110.700 516.211
202503 511.292 111.100 518.655
202506 442.156 111.700 446.114
202509 464.419 112.000 467.322
202512 547.090 113.000 545.638
202603 569.025 112.700 569.025

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円1,604.21 mean?
Zeria Pharmaceutical Co (TSE:4559) has a Cyclically Adjusted Revenue per Share of 円1,604.21 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zeria Pharmaceutical Co and its competitors.
Is Zeria Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Zeria Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,604.21. Overall, Zeria Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zeria Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Zeria Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円1,604.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zeria Pharmaceutical Co and its competitors. Zeria Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,604.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeria Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zeria Pharmaceutical Co (TSE:4559) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,509.92, compared to a current price of 円2,120.00 — trading 15.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円1,604.21. Zeria Pharmaceutical Co's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zeria Pharmaceutical Co (TSE:4559), the current Cyclically Adjusted Revenue per Share is 円1,604.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zeria Pharmaceutical Co (TSE:4559) Overvalued in 2026?

Based on GuruFocus' analysis, Zeria Pharmaceutical Co stock appears to be undervalued. The current stock price of 円2,120.00 is trading 15.5% below its estimated GF Value™ of 円2,509.92. GuruFocus considers Zeria Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4559:

  • Cyclically Adjusted Revenue per Share: 円1,604.21
  • GF Value™: 円2,509.92 vs. price of 円2,120.00 (15.5% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the TSE:4559 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zeria Pharmaceutical Co Business Description

Address 10-11, Nihonbashi Kobuna-cho, Tokyo, JPN, 103-8351
Zeria Pharmaceutical Co Ltd is a Japanese pharmaceutical company. The company through its subsidiaries engages in two business divisions which include ethical pharmaceutical products and consumer healthcare products business division. It principally manufactures, sells, imports and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, reagents, cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, and health equipment.
85GF Score

Get the complete analysis for TSE:4559

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,120.00
Price
円2,509.92
GF Value